Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 13.9%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) shares were up 13.9% during trading on Tuesday . The company traded as high as $3.33 and last traded at $2.86. Approximately 45,479 shares traded hands during mid-day trading, an increase of 169% from the average daily volume of 16,933 shares. The stock had previously closed at $2.51.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Friday, March 22nd.

Armata Pharmaceuticals Stock Up 13.9 %

The company has a market cap of $103.39 million, a PE ratio of -1.44 and a beta of 0.96.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its earnings results on Thursday, March 21st. The company reported ($0.55) earnings per share for the quarter. Armata Pharmaceuticals had a negative return on equity of 280.95% and a negative net margin of 1,524.51%. The business had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.68 million. As a group, equities analysts forecast that Armata Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC grew its holdings in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 32,777 shares of the company’s stock after acquiring an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned 0.09% of Armata Pharmaceuticals worth $137,000 as of its most recent SEC filing. 3.57% of the stock is owned by institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.